Review
Biochemistry & Molecular Biology
Silvia Buriolla, Giacomo Pelizzari, Carla Corvaja, Martina Alberti, Giada Targato, Martina Bortolot, Sara Torresan, Francesco Cortiula, Gianpiero Fasola, Alessandro Follador
Summary: Approximately 40% of NSCLC patients develop BMs, presenting a significant challenge in management. ICIs have shown promising results in advanced NSCLC, but patients with BMs are underrepresented in clinical trials. The safety and efficacy of ICIs and radiotherapy combinations are still being evaluated.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Thomas Pierret, Niccolo Giaj-Levra, Anne-Claire Toffart, Filippo Alongi, Denis Moro-Sibilot, Elisa Gobbini
Summary: Immunotherapy is an important treatment strategy for NSCLC patients, including those with brain metastases and meningeal involvement, but further research is needed due to limited data on the efficacy in these specific patient populations.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
C. Schroder, P. Windisch, J. Lutscher, D. R. Zwahlen, R. Forster
Summary: The study aimed to validate the 2022 graded prognostic assessment (GPA) for patients with brain metastases from adenocarcinoma of the lung and discuss its clinical practicability. A cohort of 137 adenocarcinoma of the lung patients was included, and NSCLC-specific GPA, Lung-molGPA, and GPA for NSCLC adenocarcinoma were calculated. The median overall survival (OS) was 15 months, and there was a significant difference in survival among different GPA groups. The study validated the 2022 GPA for NSCLC adenocarcinoma patients with brain metastases, but the practical applicability might be limited due to evolving treatments and improved overall survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Matthias Schneider, Niklas Schaefer, Christian Bode, Lars Eichhorn, Frank A. Giordano, Erdem Gueresir, Muriel Heimann, Yon-Dschun Ko, Jennifer Landsberg, Felix Lehmann, Alexander Radbruch, Christina Schaub, Katjana S. Schwab, Johannes Weller, Ulrich Herrlinger, Hartmut Vatter, Patrick Schuss
Summary: This study identified several risk factors for reduced overall survival in patients undergoing surgical treatment for non-small cell lung cancer brain metastases, including age, location of metastases, preoperative C-reactive protein levels, intraoperative blood transfusion, postoperative prolonged mechanical ventilation, and postoperative adverse events.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Ji Li, Min Wang, Shuhui Xu, Yuying Li, Jiatong Li, Jinming Yu, Hui Zhu
Summary: Brain metastases are becoming more common among NSCLC patients. Targeted therapy has shown ideal outcomes for patients with specific mutations, but wild-type patients have poor survival due to lack of effective treatments. ICIs have changed the management of NSCLC, but their efficacy in patients with brain metastases is still uncertain. Studies have suggested that ICIs may be effective in the central nervous system in select patients with high PD-L1 expression and low CNS disease burden.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Yilong Zheng, Yuxiu Yang, Min Hui Ng, Adrienne Yu Hsiang Chew, Chun Peng Goh, Christopher Yuan Kit Chua, Rahul Rathakrishnan, Yvonne Ang, Andrea Li Ann Wong, Balamurugan Vellayappan, Kejia Teo, Vincent Diong Weng Nga, Tseng Tsai Yeo, Mervyn Jun Rui Lim
Summary: The presence of perioperative seizures in patients undergoing surgical resection of brain metastases is independently associated with overall mortality, suggesting it may be a prognostic marker of poor outcome.
FRONTIERS IN ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
James Wyatt, Simon G. Powell, Salma Ahmed, James Arthur, Kiran Altaf, Shakil Ahmed, Muhammad Ahsan Javed
Summary: Inguinal lymph nodes are a rare but recognized site of metastasis in rectal adenocarcinoma. This review aims to provide a contemporary and comprehensive analysis of the published literature to aid clinical decision-making.
TECHNIQUES IN COLOPROCTOLOGY
(2023)
Article
Medicine, General & Internal
Daniele Armocida, Alessandro Pesce, Mauro Palmieri, Fabio Cofano, Giuseppe Palmieri, Paola Cassoni, Carla Letizia Busceti, Francesca Biagioni, Diego Garbossa, Francesco Fornai, Antonio Santoro, Alessandro Frati
Summary: This study investigated the relationship between EGFR mutation and the disease course, prognosis, and diagnostic imaging of brain metastases (BMs) from non-small-cell lung cancer (NSCLC). The results showed a significant correlation between EGFR mutation and the size and edema volume of BMs, as well as the incidence of seizures.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Guixiang Liao, Yuting Qian, Sumbal Arooj, Zhihong Zhao, Maosheng Yan, Zihuang Li, Hongli Yang, Tao Zheng, Gang Li, Xianming Li, Muhammad Khan
Summary: Adding anti-PD-1 therapy to whole brain radiation therapy (WBRT) in NSCLC patients with brain metastases may improve overall survival without increased adverse events. The study found that the combination treatment significantly improved survival outcomes, particularly in the EGFR wild-type subgroup. Prospective well-designed studies are needed to further investigate the additive effects of anti-PD-1 therapy in this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Nayan Lamba, Rachel Brigell Kearney, Paul J. Catalano, Michael J. Hassett, Patrick Y. Wen, Daphne A. Haas-Kogan, Ayal A. Aizer
Summary: Elderly patients with brain metastases have a poor prognosis, especially those with synchronous BM, with a median survival rate generally not exceeding 4 months; specific treatments, such as EGFR or ALK therapy, can significantly improve survival rates for NSCLC BM patients.
Review
Medicine, General & Internal
Michal Gil, Magdalena Knetki-Wroblewska, Przemyslaw Nizinski, Maciej Strzemski, Pawel Krawczyk
Summary: Metastases to the central nervous system (CNS) in non-small cell lung cancer (NSCLC) patients are difficult to treat and have a poor prognosis. Previously, radiotherapy and neurosurgery were the only treatment options. However, with the advancement of molecular biology, molecularly targeted therapies such as ALK inhibitors have been developed to penetrate the CNS and improve treatment efficacy.
ANNALS OF MEDICINE
(2023)
Article
Oncology
Wenqiang Che, Yujiao Wang, Xiangyu Wang, Jun Lyu
Summary: Based on population-based estimates, gender has a significant impact on the presence of brain metastases (BMs) in newly diagnosed malignancies and the survival of patients. Females are more likely to develop BMs at the time of diagnosis, while males with BMs have a higher risk of decreased all-cause mortality.
Article
Oncology
Wolfgang Schroeder, Markus P. H. Ghadimi, Hans Schloesser, Heike Loeser, Petra Schiller, Thomas Zander, Florian Gebauer, Hans Fuchs, Alexander Quaas, Christiane J. Bruns
Summary: This study analyzed the long-term survival and recurrence patterns after pathological complete response (pCR) with and without nodal metastases following multimodal treatment of esophageal cancer. Results showed that patients without nodal metastases had higher 5-year overall survival compared to patients with metastatic nodes. The presence of nodal metastases predicted both locoregional and distant recurrence. Follow-up recommendations should take into account the presence or absence of nodal metastases in patients with pCR, and caution should be exercised when considering watch-and-wait surveillance strategies for suspected clinical complete response.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Rebecca Rootwelt Winther, Eva Skovlund, Joakim Stray Andreassen, Lisa Arvidsson, Jonathan Halvardson, Ole Solheim, Jiri Bartek, Stein Kaasa, Marianne Jensen Hjermstad, Einar Osland Vik-Mo
Summary: Metastases to the brain are serious and often fatal. This study identified factors that predict survival after surgery for these metastases, and created a prognostic index to guide decision-making. The index was validated on patients from other hospitals and found to be effective.
Article
Oncology
Anthony B. Mariathasan, Kjetil Boye, Svein Dueland, Kjersti Flatmark, Stein G. Larsen
Summary: This study aimed to describe the frequency, pattern, and outcome of metastatic disease in locally advanced rectal cancer (LARC) patients after curative resection. Liver and lungs were the most common sites of metastasis, with factors such as involved resection margins, tumor stage, and response to chemoradiotherapy affecting metastasis development and overall survival. Selective metastasectomy was associated with better long-term outcomes in LARC patients with liver and lung metastases.
Review
Oncology
Andrea Becerril-Gaitan, Bryan F. Vaca-Cartagena, Ana S. Ferrigno, Fernanda Mesa-Chavez, Tonatiuh Barrientos-Gutierrez, Marco Tagliamento, Matteo Lambertini, Cynthia Villarreal-Garza
Summary: Patients with cancer have impaired immune response to COVID-19 vaccination compared with controls, with lower seroconversion rates and higher likelihood of SARS-CoV-2 infection.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Salvador Gutierrez Torres, Federico Maldonado Magos, Jenny G. Turcott, Juan-Manuel Hernandez-Martinez, Bernardo Cacho-Diaz, Andres F. Cardona, Aida Mota-Garcia, Francisco Lozano Ruiz, Maritza Ramos-Ramirez, Oscar Arrieta
Summary: This study aimed to identify prognostic factors associated with survival after brain re-irradiation to develop a new prognostic index. The independent prognostic factors for shorter survival after re-irradiation were identified as age >50 years, uncontrolled primary tumor, lesion size >20mm, and an interval <12 months between radiation treatments. The new brain re-irradiation index (BRI) can be easily implemented for prognostic classification of cancer patients with progressive or recurrent brain metastases.
Review
Oncology
Natalia Ayala, Sabrina Barchuk, Gloria Inurrigarro, Constanza Celano, Jorge Luis Soriano-Garcia, Patricia Bolanos, Monica Mohs-Alfaro, Hector Tapia-Gonzalez, Ramon Perez-Martinez, Suraj Samtani, Isabel Alvarado-Cabrero, Cynthia Villarreal-Garza, Jaime Tamez-Salazar, Gerardo Magallanes-Garza, Daniela Vazquez, Janeth Castro, Gabriela S. Gomez-Macias, Ana Ferrigno, Zaida Morante, Sheila Vilchez, Jose Manuel Cotrina, Franco Doimi, Guianeya Santander, Carlos Acevedo, Virginia Ortega, Fernando Lavista, Lucia Richter, Mario Gianella, Maria Paredes, Christian H. Flores-Balcazar, Joseph A. Pinto, Henry L. Gomez
Summary: The Breast Cancer Revealed initiative aims to understand the status of breast cancer care across different stages, such as prevention, detection, diagnosis, treatment, and healthcare capacity. A panel of experts from 11 Latin American countries has identified strategies and priorities, including implementing prevention policies, improving primary healthcare for screening, ensuring infrastructure for effective diagnoses, multidisciplinary treatment teams, access to various treatments for all patients, and a coordinated system from primary to specialized care. Prioritizing high-impact strategies for breast cancer control in resource-limited regions can lead to better clinical outcomes and quality of life for patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Eric Ortiz Valdez, Claudia Rangel-Escareno, Juan Antonio Matus Santos, Rafael Vazquez Romo, Alberto Guijosa, Cynthia Villarreal-Garza, Oscar Arrieta, Ruben Rodriguez-Bautista, Claudia Caro-Sanchez, Alette Ortega Gomez
Summary: This study aimed to assess the clinical, pathological and prognostic characteristics of TNBC in a Mexican-based cohort. By analyzing gene expression, 55 patients were classified into 6 TNBC molecular subtypes. The immunomodulatory subtype had the best overall survival, while the Basal-like-2 subtype had the worst overall survival. The results are important for implementing clinical-molecular models for TNBC patient care.
MOLECULAR AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jhajaira M. Araujo, Andrea C. Gomez, Winston Zingg-De Jongh, Jhon Ausejo, Ivan Cordova, Luis J. Schwarz, Denisse Bretel, Williams Fajardo, Luis G. Saravia-Huarca, Joshuan Barboza-Meca, Zaida Morante, Juan R. Guillen, Henry Gomez, Nadezhda K. Cardenas, Lady Hernandez, Walter Melo, Cynthia Villarreal-Garza, Christian Caglevic, Carolina Palacio, Hector Garcia, Gerson Mejia, Claudio Flores, Carlos Vallejos, Joseph A. Pinto
Summary: A study was conducted in Peru to assess the feasibility of breast cancer screening (BCS) and develop an instrument to evaluate knowledge and barriers associated with BCS. The results highlight the urgent need for extensive education and awareness about BCS in Peru.
ECANCERMEDICALSCIENCE
(2023)
Review
Oncology
Juan-Manuel Hernandez-Martineza, Rafael Rosellc, Oscar Arrietaa
Summary: ATM is a key kinase involved in the repair of DNA double-strand breaks and is associated with an increased risk of developing lung adenocarcinoma. Little is known about the contribution of immune dysfunction to lung cancer susceptibility in ATM-deficient patients. The introduction of targeted therapies and immunotherapies necessitates a reexamination of therapeutic approaches for ATM-deficient lung cancers.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Pedro Barrios-Bernal, Jose Lucio-Lozada, Maritza Ramos-Ramirez, Norma Hernandez-Pedro, Oscar Arrieta
Summary: This study aimed to investigate the effects of the combination of sotorasib and metformin on cytotoxicity, apoptosis, and the MAPK and mTOR pathways in lung cancer cells. The results showed that metformin enhanced the effect of sotorasib in cells with KRAS mutations and had a slight enhancing effect in cells without KRAS mutations. Additionally, the combination treatment synergistically enhanced cytotoxicity and apoptosis induction, and significantly inhibited the MAPK and AKT-mTOR pathways, particularly in KRAS-mutated cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Cynthia Villarreal-Garza, Ana S. S. Ferrigno, Cynthia De la Garza-Ramos, Daniela Vazquez-Juarez, Brizio Moreno-Jaime, Yuly Remolina-Bonilla, Manuel Segura-Gonzalez, Ignacio Mariscal-Ramirez, Florencia Perazzo, Georgina Garnica-Jaliffe, Silvia Neciosup-Delgado, Emilio Conde-Flores, Shirly Mysler, Arlette Hernandez-Ayala, Alondra Barajas-Sanchez, Maria del Socorro Rios Mercado, Nelia Maria Noh-Vazquez, Ricardo Garcia-Rodriguez, Ana Platas, Jaime Tamez-Salazar, Teresa Mireles-Aguilar, Alejandra Platas
Summary: This study aimed to evaluate the impact of written educational materials on breast cancer patients. It found that customizable educational brochures can increase patients' understanding of breast cancer treatment and improve their ability to participate in decision-making.
Article
Medicine, Research & Experimental
Paula Cabrera-Galeana, Nancy Reynoso-Noveron, Carlos Gonzalez-Nunez, Oscar Arrieta, Juan Torres, Silvia Allende, Diana Vilar-Compte, Consuelo Diaz, Claudia Cano, Miguel Alvarez, Alejandro Mohar
Summary: This study aimed to identify prognostic factors associated with mortality in patients with active cancer and severe COVID-19, as well as evaluate the correlation between oncologic codes and mortality. The results indicated that the red oncologic code, low oxygen saturation, chronic corticosteroid use, and high D-dimer level were the main predictive factors related to mortality.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Immunology
Norma Hernandez-Pedro, Marisol Arroyo-Hernandez, Pedro Barrios-Bernal, Eunice Romero-Nunez, Victor A. Sosa-Hernandez, Santiago avila-Rios, Jose Luis Maravillas-Montero, Rogelio Perez-Padilla, Diego de Miguel-Perez, Christian Rolfo, Oscar Arrieta
Summary: Immune dysregulation and cancer treatment may affect the protection of SARS-CoV-2 vaccination. NSCLC patients undergoing oncological treatment, especially chemotherapy and tyrosine kinase inhibitors, have impaired antibody generation after receiving the vaccine. Patients receiving immunotherapy did not generate antibodies.
Review
Oncology
Daniela Cardenas-Fernandez, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chavez-Tapia, Emilio Conde-Flores, Andres F. Cardona, Oscar Arrieta
Summary: The identification of EGFR mutations in lung adenocarcinoma has led to personalized medicine and the use of EGFR-TKIs, which inhibit the signaling pathways and improve survival rates. However, diarrhea is a common adverse effect of EGFR-TKIs and can have significant impacts on patient's quality of life. Careful management of diarrhea, including dietary changes and supplementation, can reduce its incidence and improve patients' well-being.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Enrique Caballe-Perez, Norma Hernandez-Pedro, Maritza Ramos-Ramirez, Pedro Barrios-Bernal, Eunice Romero-Nunez, Jose Lucio-Lozada, Santiago Avila-Rios, Gustavo Reyes-Teran, Andres F. Cardona, Oscar Arrieta
Summary: This study comprehensively characterizes the molecular heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) in Latin American patients for the first time, highlighting the prognostic impact of diverse molecular profiles and emphasizing the need for further validation in larger cohorts.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Alberto Alvarado-Miranda, Fernando Ulises Lara-Medina, Wendy R. Munoz-Montano, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesus Alberto Limon Rodriguez, Claudia Haydee Arce Salinas, Alberto Guijosa, Oscar Arrieta
Summary: Evidence suggests that long low-dose capecitabine regimens combined with endocrine therapy have a synergistic effect and may improve overall survival in hormone receptor-positive, HER2-negative, metastatic breast cancer patients. The XELIA regimen showed longer progression-free survival and higher overall response rates compared to aromatase inhibitors and capecitabine alone. Larger studies are needed to confirm these findings.
Review
Oncology
Gustavo Gossling, Taiane F. Rebelatto, Cynthia Villarreal-Garza, Ana S. Ferrigno, Denisse Bretel, Raul Sala, Juliana Giacomazzi, William N. N. William Jr, Gustavo Werutsky
Summary: Progress has been achieved in cancer control initiatives in Latin America and the Caribbean, but there are still gaps, such as a lack of clinical trials. This article focuses on the current status of cancer research in the region, highlighting academic research groups and investigator-initiated research. Despite challenges in funding, regulations, and skilled workforce, progress has been observed in clinical trial development and scientific productivity. However, more funding from governments and private foundations is needed to support oncology trials and address region-specific cancer therapies and management.
Article
Oncology
Alejandro Aviles-Salas, Diego A. A. Diaz-Garcia, Luis Lara-Mejia, Andres F. Cardona, Mario Orozco-Morales, Rodrigo Catalan, Norma Y. Y. Hernandez-Pedro, Eduardo Rios-Garcia, Maritza Ramos-Ramirez, Oscar Arrieta
Summary: This study assessed the potential biomarker role of LKB1 expression in guiding clinical therapy. The loss of LKB1 was associated with non-smokers, absence of wood smoke exposure, and EGFR wild-type status. The results showed that LKB1 loss was significantly associated with worse progression-free survival and overall survival in advanced NSCLC, indicating its prognostic role.
